Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma.

RET RET-inhibitor RET-rearrangement differentiated thyroid cancer papillary thyroid carcinoma pralsetinib

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 12 09 2022
accepted: 18 11 2022
entrez: 29 12 2022
pubmed: 30 12 2022
medline: 30 12 2022
Statut: epublish

Résumé

We are recently faced with a progressive evolution of the therapeutic paradigm for radioiodine refractory differentiated thyroid cancer (RAI-R DTC), since the advent of tissue agnostic inhibitors. Thus, tumor genotype assessment is always more relevant and is playing a crucial role into clinical practice. We report the case of an elderly patient with advanced papillary thyroid carcinoma (PTC) harboring

Identifiants

pubmed: 36578928
doi: 10.3389/fonc.2022.1042525
pmc: PMC9792137
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1042525

Informations de copyright

Copyright © 2022 Nannini, Repaci, Ricco, Ianni, Golemi, Maiolo, Ferrari, Natali, Rizzini, Monari, Solaroli, De Leo, Maloberti, Pantaleo, De Biase and Tallini.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Thyroid. 2017 Feb;27(2):182-188
pubmed: 27849443
Adv Anat Pathol. 2001 Nov;8(6):345-54
pubmed: 11707626
J Clin Pathol. 2022 Jul;75(7):488-492
pubmed: 33820865
Am J Surg Pathol. 2006 Feb;30(2):216-22
pubmed: 16434896
Histopathology. 2016 Jul;69(1):45-53
pubmed: 26568156
Eur J Endocrinol. 2022 Apr 29;186(6):631-643
pubmed: 35333737
Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501
pubmed: 34118198
Mod Pathol. 2007 Jul;20(7):779-87
pubmed: 17464312
J Clin Endocrinol Metab. 2006 Sep;91(9):3603-10
pubmed: 16772343
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Ann Surg Oncol. 2022 Mar 1;:
pubmed: 35230579
Genes (Basel). 2020 Apr 15;11(4):
pubmed: 32326537
Ann Surg. 2015 Sep;262(3):519-25; discussion 524-5
pubmed: 26258321
Ann Oncol. 2022 Jul;33(7):674-684
pubmed: 35491008
J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6
pubmed: 11443191
N Engl J Med. 2020 Aug 27;383(9):825-835
pubmed: 32846061
PLoS Genet. 2016 Aug 05;12(8):e1006239
pubmed: 27494611
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Mod Pathol. 2020 Dec;33(12):2458-2472
pubmed: 32737449
Pathol Oncol Res. 2020 Jan;26(1):507-513
pubmed: 30467698
J Clin Endocrinol Metab. 2006 Jun;91(6):2414-23
pubmed: 16595592
Trends Cancer. 2021 Dec;7(12):1074-1088
pubmed: 34391699
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Cancer Res. 2008 Sep 1;68(17):7176-82
pubmed: 18757433
Lab Invest. 2004 Dec;84(12):1557-70
pubmed: 15502856

Auteurs

Margherita Nannini (M)

Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Andrea Repaci (A)

Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Gianluca Ricco (G)

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Manuela Ianni (M)

UO Ricerca e Innovazione, Clinical Trials Centre, IRCCS Azienda Ospedaliera Sant'Orsola Malpighi-Università di Bologna, Bologna, Italy.

Arber Golemi (A)

Nuclear Medicine Division, IRCCS AOU Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Vincenzo Maiolo (V)

Radiology Uniti, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S Orsola-Malpighi, Bologna, Emilia-Romagna, Italy.

Marco Ferrari (M)

Interventional Pulmonology Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Filippo Natali (F)

Interventional Pulmonology Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Elisa Lodi Rizzini (EL)

Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Fabio Monari (F)

Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Erica Solaroli (E)

Endocrinology Unit, Azienda USL of Bologna, Bologna, Italy.

Antonio De Leo (A)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Thais Maloberti (T)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Maria A Pantaleo (MA)

Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Dario De Biase (D)

Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Pharmacy and Biotechnology (FaBit), University of Bologna, Bologna, Italy.

Giovanni Tallini (G)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Classifications MeSH